This further expands the range of applications for TREM‐1 SCHOOL peptide sequence‐based formulations from oncology and sepsis 18 to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, colitis and inflammatory bowel disease, where blockade of TREM‐1 is of clinical importance. This evidence concerns the gene TREM1 and autoimmune disease.